findmyKOL
Clinical trialNCT02386826CompletedPhase 1Interventional

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

SponsorSCRI Development Innovations, LLCEnrollment65Colorectal CancerGlioblastoma MultiformeGliosarcomaRenal Cell Carcinoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine whether the combination of two agents, INC280 and bevacizumab, is safe and effective when administered to patients with Glioblastoma Multiforme (GBM) who have progressed after receiving prior therapy or who have unresectable GBM.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Sarah Cannon Research Institute at Healthone

    Denver, Colorado, United States

  • Yale School of Medicine

    New Haven, Connecticut, United States

  • Hca Midwest - Kansas City

    Kansas City, Missouri, United States

  • Oklahoma University Health Science Center

    Oklahoma City, Oklahoma, United States

  • Tennessee Oncology Pllc

    Nashville, Tennessee, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

INC280Bevacizumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
22 Sept 2015
Primary completion
31 Jul 2021
Completion
23 Aug 2023
Last update posted
21 Sept 2023
Registered enrollment
65
Registry id
NCT02386826
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.